Form 4: Acurx Pharmaceuticals Director Receives Stock Options

Director Robert J. DeLuccia was granted 37,100 stock options in Acurx Pharmaceuticals, Inc. as part of a compensation plan.

Summary

• Director Robert J. DeLuccia received a grant of 37,100 stock options on April 20, 2026.
• The options have an exercise price of $2.36 per share.
• The options vest in 36 equal monthly installments starting from the grant date.
• The options expire on April 20, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which is neutral for the stock price.

Positives

• Aligns director interests with long-term shareholder value through equity-based compensation.

Negatives

• Results in potential future dilution of existing shareholders upon exercise of the options.

Risks

• Market price volatility could impact the value of the options and the incentive structure for the director.

Future Outlook

The options vest over a 36-month period, indicating a long-term retention and performance incentive for the director.

Industry Context

StockSavvy.ai notes that equity grants to directors are standard practice in the biotechnology sector to ensure leadership alignment with clinical and commercial milestones.

Comparison to Industry Standards

• The use of monthly vesting schedules over three years is consistent with standard corporate governance practices for small-cap biotech firms.

Stakeholder Impact

• Shareholders may experience minor dilution if these options are exercised in the future.

Next Steps

• Vesting of options in 36 equal monthly installments.

Key Dates

Keywords

Acurx Pharmaceuticals, ACXP, Form 4, Insider Trading, Stock Options, Director Compensation